Stockreport

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook [Yahoo! Finance]

Bicara Therapeutics Inc.  (BCAX) 
PDF Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 Anticipates multiple expansion cohort data readouts in 2026 t [Read more]